Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics

摘要: Peritoneal carcinomatosis remains a significant cause of morbidity and is marker poor prognosis in range malignancies, including those the gastrointestinal gynaecological tracts. In these cases, regional therapy has been explored as treatment strategy to take advantage prolonged confinement such tumours within peritoneal cavity steep dose-response relationship for most cytotoxic agents. The pharmacokinetic rationale based on exploiting peritoneal-plasma barrier, which slows rate drug clearance from systemic compartments creates concentration differential favour cavity. This allows higher concentrations, thus increased cytotoxicity, be achieved at site tumour There pharmacodynamic evidence number clinical trials support translation advantages intraperitoneal chemotherapy into benefit. However, its application controversial because concerns regarding distribution, technical challenges toxicity associated with delivery relevance studies undertaken. purpose this review summarize delivery, performed ovarian, colorectal gastric cancers, outline future directions mode treatment.